This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaffe, C. C. Search for Related Content PubMed PubMed Citation Articles by Jaffe, C. C. Social Bookmarking                            What's this?

Measures of Response: RECIST, WHO, and New Alternatives

From the Diagnostic Imaging Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

Address reprint requests to C. Carl Jaffe, MD, 6130 Executive Blvd, Room 6050, Bethesda, MD 20892-7412; e-mail: jaffec1{at}mail.nih.gov

RECIST (Response Evaluation Criteria in Solid Tumors) is a widely employed method introduced in 2000 to assess change in tumor size in response to therapy. The simplicity of the technique, however, contrasts sharply with the increasing sophistication of imaging instrumentation. Anatomically based imaging measurement, although supportive of drug development and key to some accelerated drug approvals, is being pressed to improve its methodologic robustness, particularly in the light of more functionally-based imaging that is sensitive to tissue molecular response such as fluorodeoxyglucose positron emission tomography. Nevertheless ready availability of computed tomography and magnetic resonance imaging machines largely assures anatomically based imaging a continuing role in clinical trials for the foreseeable future. Recent advances in image processing enabled by the computational power of modern clinical scanners open a considerable opportunity to characterize tumor response to therapy as a complement to image acquisition. Various alternative quantitative volumetric approaches have been proposed but have yet to gain wide acceptance by clinical and regulatory communities, nor have these more complex techniques shown incontrovertible evidence of greater reproducibility or predictive value of clinical events and outcome. Unless plans are created for clinical trials that incorporate the design needed to prove the added value and unique clinical utility of these novel approaches, any theoretical benefit of these more elaborate methods could remain unfulfilled.

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim {beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer Cancer Res., November 15, 2009; 69(22): 8620 - 8628. [Abstract] [Full Text] [PDF]

				G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas, and C. A. Papadimitriou Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., August 1, 2009; 20(8): 1362 - 1368. [Abstract] [Full Text] [PDF]

				J. C. KIM, E. S. SHIN, C. W. KIM, S. A. ROH, D. H. CHO, Y. S. NA, T. W. KIM, M. B. KIM, Y. L. HYUN, S. RO, et al. In Vitro Evaluation of Histone Deacetylase Inhibitors as Combination Agents for Colorectal Cancer Anticancer Res, August 1, 2009; 29(8): 3027 - 3034. [Abstract] [Full Text] [PDF]

				M H S E DARKEH, C SUZUKI, and M R TORKZAD The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST) Br. J. Radiol., August 1, 2009; 82(980): 681 - 686. [Abstract] [Full Text] [PDF]

				J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAOUI, S. VERBEKE, L. VENAT-BOUVET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, et al. Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans Anticancer Res, July 1, 2009; 29(7): 2563 - 2568. [Abstract] [Full Text] [PDF]

				S. Stacchiotti, P. Collini, A. Messina, C. Morosi, M. Barisella, R. Bertulli, C. Piovesan, P. Dileo, V. Torri, A. Gronchi, et al. High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment--Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria Radiology, May 1, 2009; 251(2): 447 - 456. [Abstract] [Full Text] [PDF]

				E. A. Hirschowitz and J. R. Yannelli Immunotherapy for Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 224 - 232. [Abstract] [Full Text] [PDF]

				M. A. Gavrielides, L. M. Kinnard, K. J. Myers, and N. Petrick Noncalcified Lung Nodules: Volumetric Assessment with Thoracic CT Radiology, April 1, 2009; 251(1): 26 - 37. [Abstract] [Full Text] [PDF]

				A. I. Daud, R. C. DeConti, S. Andrews, P. Urbas, A. I. Riker, V. K. Sondak, P. N. Munster, D. M. Sullivan, K. E. Ugen, J. L. Messina, et al. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma J. Clin. Oncol., December 20, 2008; 26(36): 5896 - 5903. [Abstract] [Full Text] [PDF]

				E. T. Lam, C. L. O'Bryant, M. Basche, D. L. Gustafson, N. Serkova, A. Baron, S. N. Holden, J. Dancey, S. G. Eckhardt, and L. Gore A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors Mol. Cancer Ther., December 1, 2008; 7(12): 3685 - 3694. [Abstract] [Full Text] [PDF]

				H. C. Manning, N. B. Merchant, A. C. Foutch, J. M. Virostko, S. K. Wyatt, C. Shah, E. T. McKinley, J. Xie, N. J. Mutic, M. K. Washington, et al. Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7413 - 7422. [Abstract] [Full Text] [PDF]

				G. S. Dorfman, D. C. Sullivan, M. D. Schnall, L. M. Matrisian, and for the Translational Research Working Group The Translational Research Working Group Developmental Pathway for Image-Based Assessment Modalities Clin. Cancer Res., September 15, 2008; 14(18): 5678 - 5684. [Abstract] [Full Text] [PDF]

				I. Iwanicki-Caron, F. Di Fiore, I. Roque, E. Astruc, M. Stetiu, A. Duclos, D. Tougeron, S. Saillard, S. Thureau, J. Benichou, et al. Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer J. Clin. Oncol., August 1, 2008; 26(22): 3681 - 3686. [Abstract] [Full Text] [PDF]

				L. E. Dodd, E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense? J. Clin. Oncol., August 1, 2008; 26(22): 3791 - 3796. [Abstract] [Full Text] [PDF]

				M. Law, R. J. Young, J. S. Babb, N. Peccerelli, S. Chheang, M. L. Gruber, D. C. Miller, J. G. Golfinos, D. Zagzag, and G. Johnson Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Radiology, May 1, 2008; 247(2): 490 - 498. [Abstract] [Full Text] [PDF]

				A. Hajitou, D. C. Lev, J. A. F. Hannay, B. Korchin, F. I. Staquicini, S. Soghomonyan, M. M. Alauddin, R. S. Benjamin, R. E. Pollock, J. G. Gelovani, et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging PNAS, March 18, 2008; 105(11): 4471 - 4476. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109. [Abstract] [Full Text] [PDF]